Microbiota transplant therapy and autism: lessons for the clinic.
James B AdamsThomas J BorodyDae-Wook KangAlexander KhorutsRosa Krajmalnik-BrownMichael J SadowskyPublished in: Expert review of gastroenterology & hepatology (2019)
Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (MTT), a type of intensive intestinal microbiota transplantation (IMT), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews IMT, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive MTT for autism.Expert opinion: An open-label study and a two-year follow-up suggest that MTT is relatively safe and effective in significantly reducing gastrointestinal disorders and autism symptoms, changing the gut microbiome structure, and increasing gut microbial diversity. Further research with larger, randomized, double-blind, placebo-controlled studies is warranted.
Keyphrases
- autism spectrum disorder
- placebo controlled
- double blind
- intellectual disability
- attention deficit hyperactivity disorder
- phase iii
- clinical trial
- phase ii
- young adults
- study protocol
- open label
- stem cells
- microbial community
- radiation therapy
- cell therapy
- randomized controlled trial
- squamous cell carcinoma
- mesenchymal stem cells
- replacement therapy
- sleep quality
- rectal cancer
- working memory
- case control